ArticleBlood advances2025

Advantages of a genomic DNA-based next-generation sequencing assay for detection of mutant NPM1 measurable residual disease in AML.

Christian M Vonk et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.